[go: up one dir, main page]

HUE056019T2 - Polipeptidek komplement aktiváció gátlására - Google Patents

Polipeptidek komplement aktiváció gátlására

Info

Publication number
HUE056019T2
HUE056019T2 HUE16828743A HUE16828743A HUE056019T2 HU E056019 T2 HUE056019 T2 HU E056019T2 HU E16828743 A HUE16828743 A HU E16828743A HU E16828743 A HUE16828743 A HU E16828743A HU E056019 T2 HUE056019 T2 HU E056019T2
Authority
HU
Hungary
Prior art keywords
polypeptides
complement activation
inhibiting complement
inhibiting
activation
Prior art date
Application number
HUE16828743A
Other languages
English (en)
Inventor
Stefan Michelfelder
Karsten Häffner
Original Assignee
eleva GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by eleva GmbH filed Critical eleva GmbH
Publication of HUE056019T2 publication Critical patent/HUE056019T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
HUE16828743A 2015-12-23 2016-12-23 Polipeptidek komplement aktiváció gátlására HUE056019T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102015016665 2015-12-23

Publications (1)

Publication Number Publication Date
HUE056019T2 true HUE056019T2 (hu) 2022-01-28

Family

ID=57838331

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16828743A HUE056019T2 (hu) 2015-12-23 2016-12-23 Polipeptidek komplement aktiváció gátlására

Country Status (18)

Country Link
US (2) US10640540B2 (hu)
EP (1) EP3394089B1 (hu)
JP (2) JP6771568B2 (hu)
KR (1) KR20180091097A (hu)
CN (1) CN108699121B (hu)
AU (1) AU2016375183B2 (hu)
CA (1) CA3009393C (hu)
DK (1) DK3394089T3 (hu)
ES (1) ES2895256T3 (hu)
HR (1) HRP20211608T1 (hu)
HU (1) HUE056019T2 (hu)
IL (1) IL260182B2 (hu)
LT (1) LT3394089T (hu)
MX (1) MX2018007392A (hu)
PL (1) PL3394089T3 (hu)
PT (1) PT3394089T (hu)
SI (1) SI3394089T1 (hu)
WO (1) WO2017109208A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3675854T3 (fi) 2017-08-31 2025-04-07 Novartis Ag Piperidinyyli-indolijohdannaisia käytettäväksi c3-glomerulopatian hoidossa
JP2020533414A (ja) 2017-09-11 2020-11-19 インサイドアウトバイオ インコーポレイテッド 腫瘍の免疫原性を増強する方法および組成物
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
DE102018120016B4 (de) * 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
EP4153580A1 (en) 2020-05-18 2023-03-29 Novartis AG Crystalline form of lnp023
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
TW202523706A (zh) * 2023-11-13 2025-06-16 大陸商瀋陽三生製藥有限責任公司 一種靶向C3b的雙功能融合蛋白及其製備方法與用途
EP4559472A1 (en) * 2023-11-24 2025-05-28 Universität Ulm Complement modulator
WO2025109172A1 (en) * 2023-11-24 2025-05-30 Universität Ulm Complement modulator
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097440B1 (en) * 1982-06-14 1986-09-24 The Upjohn Company Method and kit for removing and assaying complement system fragments
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ZA200807620B (en) * 2006-03-08 2009-12-30 Archemix Corp Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
AR069130A1 (es) 2007-11-02 2009-12-30 Novartis Ag Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
HRP20230167T1 (hr) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Postupci i pripravci za liječenje poremećaja povezanih s komplementom
JP5740772B2 (ja) * 2009-08-31 2015-07-01 アイビーシー ファーマスーティカルズ,インコーポレイテッド 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用
CN103168048B (zh) * 2010-06-09 2017-02-15 酶原遗传学有限公司 二聚vstm3融合蛋白和相关的组合物和方法
CN110075294A (zh) * 2011-04-08 2019-08-02 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
CN102978204B (zh) * 2011-11-11 2018-06-08 张康 Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法
WO2013142362A1 (en) * 2012-03-19 2013-09-26 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
FR3015484A1 (fr) 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
US20220009979A1 (en) * 2018-08-22 2022-01-13 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US20220220169A1 (en) * 2019-05-15 2022-07-14 Insideoutbio, Inc. Modular Therapeutics for the Treatment of Inflammatory Diseases and Cancer
WO2021247487A1 (en) * 2020-06-01 2021-12-09 Medical University Of South Carolina Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders

Also Published As

Publication number Publication date
ES2895256T3 (es) 2022-02-18
EP3394089A1 (en) 2018-10-31
IL260182B1 (en) 2023-08-01
US11591378B2 (en) 2023-02-28
IL260182B2 (en) 2023-12-01
IL260182A (en) 2018-07-31
KR20180091097A (ko) 2018-08-14
BR112018012844A2 (pt) 2018-12-04
SI3394089T1 (sl) 2021-12-31
US20200277347A1 (en) 2020-09-03
AU2016375183A1 (en) 2018-07-19
CN108699121A (zh) 2018-10-23
EP3394089B1 (en) 2021-07-28
DK3394089T3 (da) 2021-11-01
PL3394089T3 (pl) 2022-01-17
US10640540B2 (en) 2020-05-05
CN108699121B (zh) 2023-07-04
JP2020167999A (ja) 2020-10-15
PT3394089T (pt) 2021-11-03
CA3009393A1 (en) 2017-06-29
AU2016375183B2 (en) 2021-01-21
JP2019508022A (ja) 2019-03-28
LT3394089T (lt) 2021-11-25
WO2017109208A1 (en) 2017-06-29
CA3009393C (en) 2023-08-22
HRP20211608T1 (hr) 2022-01-21
MX2018007392A (es) 2018-08-15
US20190300589A1 (en) 2019-10-03
JP6771568B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
ZA201802261B (en) Polypeptides
DK3478217T3 (en) Historisk scanningsreference for intraorale scanninger
IL255767A (en) New polypeptides
DK3410992T3 (en) Tilbagetrækkeligt udløb til stomipose
IL254577A0 (en) polypeptides
DK3386454T3 (en) Forbinding til hudpleje i fugtigt miljø
DK3325223T3 (en) Tandhjulspakke til robotarme
IL260182A (en) Polypeptides to inhibit complement activation
DK3770053T3 (en) Batterilås til en elcykel
IL259249A (en) cd40l inhibitory polypeptides
ZA201704366B (en) Il-17a-binding polypeptides
SG11201706882VA (en) Polypeptides
HUE042660T2 (hu) Olvadóbiztosító elem
DK3259217T3 (en) Transportsystem til blodprøver
DK3481437T3 (en) Precursorer til radiofluorering
ZA201705934B (en) Peptides for inhibiting angiogenesis
DK3264929T3 (en) Tilpasningsdygtigt fodtøj til fodboldspil
GB201517119D0 (en) Cover
GB201516537D0 (en) Accessibility Switch
GB201507950D0 (en) Cover up for pants
DK3430280T3 (en) Magnetisk leje til en turbomaskine
GB201617952D0 (en) For you
GB201605290D0 (en) Pills
GB201515245D0 (en) Novel polypeptides
GB201511998D0 (en) Cover